Skip to main content
SpringerLink
Log in

Delayed neurotoxicity of intraventricular interleukin-2: A case report

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Summary

A case is reported of a 40 year old woman treated with intraventricular IL-2 for leptomeningeal disease who developed progressive cognitive dysfunction. This deterioration started 3 months post-treatment and worsened over the ensuing 4 years. MRI revealed white matter abnormalities that were not present on the pretreatment scan. Although free of disease, the patient has a subcortical dementia and is unable to work. The potential for progressive brain injury and subsequent disability related to intraventricular IL-2 therapy is discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Denicoff KD, Rubinow DR, Papa MZet al.: The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 107: 293–300, 1987

    Google Scholar 

  2. Jacobs SK, Wilson DJ, Kornblith PL, Grimm EA: Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: Phase I trial. Cancer Res 46: 2010–2104, 1986

    Google Scholar 

  3. Saris SC, Rosenberg SA, Friedman RB, Rubin JT, Barba D, Oldfield EH: Penetration of recombinant interleukin-2 across the blood-cerebrospinal fluid barrier. J Neurosurg 69: 29–34, 1988

    Google Scholar 

  4. Bernard JT, Ameriso S, Kempf RA, Rosen P, Mitchell MS, Fisher M: Transient focal neurologic deficits complicating interleukin-2 therapy. Neurology 40: 154–155, 1990

    Google Scholar 

  5. Ellison MD, Krieg RJ, Povlishock JT: Differential central nervous system responses following single and multiple recombinant interleukin-2 infusions. J Neuroimmunol 28: 249–260, 1990

    Google Scholar 

  6. Mier JW, Vachino G, Lempner MSet al.: Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects. Blood 76: 1933–1940, 1990

    Google Scholar 

  7. Ellison MD, Merchant RE: Appearance of cytokine-associated central nervous system myelin damage coincides temporally with serum tumor necrosis factor induction after recombinant interleukin-2 infusion in rats. J Neuroimmunol 33: 245–251, 1991

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neuro-Oncology, The University of Texas, Anderson Cancer Center, Houston, TX, USA

    Christina A. Meyers & W. K. Alfred Yung

Authors
  1. Christina A. Meyers
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. K. Alfred Yung
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Meyers, C.A., Yung, W.K.A. Delayed neurotoxicity of intraventricular interleukin-2: A case report. J Neuro-Oncol 15, 265–267 (1993). https://doi.org/10.1007/BF01050073

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01050073

Key words

Search

Navigation